A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)

被引：2

作者：

Miura, S. ^{[1
]}

Hsia, T. ^{[2
]}

Hung, J. ^{[3
]}

Jung, H. A. ^{[4
]}

Shih, J. ^{[5
]}

Park, C. ^{[6
,7
]}

Lee, S. H. ^{[8
]}

Okamoto, T. ^{[9
]}

Ahn, H. K. ^{[10
]}

Lee, Y. C. ^{[11
]}

Sato, Y. ^{[12
]}

Lee, S. S. ^{[13
]}

Mascaux, C. ^{[14
]}

Daoud, H. ^{[15
]}

Maerten, A. ^{[15
]}

Popat, S. ^{[16
,17
]}

机构：

[1] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[2] China Med Univ, Dept Resp Therapy, Dept Internal Med, China Med Univ Hosp, Taichung, Taiwan

[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[5] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[6] Chonnam Natl Univ, Sch Med, Dept Internal Med, Hwasun, South Korea

[7] Hwasun Hosp, Hwasun, South Korea

[8] Kyung Hee Univ, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, Seoul, South Korea

[9] Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan

[10] Gachon Univ, Gil Med Ctr, Div Med Oncol, Incheon, South Korea

[11] Chonbuk Natl Univ, Res Inst Clin Med, Biomed Res Inst, Dept Internal Med,Chonbuk Natl Univ Hosp,Med Sch, Jeonju, South Korea

[12] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[13] Inje Univ, Coll Med, Haeundae Paik Hosp, Busan, South Korea

[14] Strasbourg Univ, Strasbourg Univ Hosp, Dept Pulm, Strasbourg, France

[15] Boehringer Ingelheim Int Gmbh, Ingelheim, Germany

[16] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England

[17] Inst Canc Res, London, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期

关键词：

D O I：

10.1016/j.jtho.2021.08.531

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P50.03

引用

页码：S1115 / S1116

页数：2

共 50 条

[1] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
Miura, S.
Hsia, T-C.
Hung, J-Y.
Jung, H. A.
Shih, J-Y.
Park, C-K.
Lee, S. H.
Okamoto, T.
Ahn, H. K.
Lee, Y. C.
Sato, Y.
Lee, S. S.
Mascaux, C.
Daoud, H.
Maerten, A.
Popat, S.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
[2] Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
Miura, Satoru
Hsia, Te-Chun
Hung, Jen-Yu
Jung, Hyun Ae
Shih, Jin-Yuan
Park, Cheol-Kyu
Lee, Seung Hyeun
Okamoto, Tatsuro
Ahn, Hee Kyung
Lee, Yong Chul
Sato, Yuki
Lee, Sung Sook
Mascaux, Celine
Daoud, Hasan
Maerten, Angela
Popat, Sanjay
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations
Miura, S.
Hsia, T-C.
Hung, J-Y.
Jung, H. A.
Shih, J-Y.
Yang, T-Y.
Park, C-K.
Lee, S. H.
Okamoto, T.
Ahn, H. K.
Lee, Y. C.
Sato, Y.
Lee, S. S.
Mascaux, C.
Daoud, H.
Maerten, A.
Popat, S.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S776 - S777
[4] Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
Kaen, D.
Tsou, F.
Lupinacci, L.
Puparelli, C.
Minatta, J.
Rizzo, M.
Berutti, S.
Di Giovanni, R.
Ferreira, Y.
Recondo, G.
Carranza, O.
Flores, M.
Aman, E.
Di Mario, G.
Pini, A.
Castagneris, N.
Roa, M.
Enrico, D.
Martin, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S668
[5] UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations.
Miura, Satoru
Hsia, Te-Chun
Hung, Jen-Yu
Jung, Hyun Ae
Shih, Jin-Yuan
Yang, Tsung-Ying
Park, Cheol-Kyu
Lee, Seung Hyeun
Okamoto, Tatsuro
Ahn, Hee Kyung
Lee, Yong Chul
Sato, Yuki
Lee, Sung Sook
Mascaux, Celine
Daoud, Hasan
Maerten, Angela
Popat, Sanjay
[J]. CANCER RESEARCH, 2021, 81 (13)
[6] Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
Passaro, Antonio
Prelaj, Arsela
Bonanno, Laura
Tiseo, Marcello
Tuzi, Alessandro
Proto, Claudia
Chiari, Rita
Rocco, Danilo
Genova, Carlo
Sini, Claudio
Cortinovis, Diego
Pilotto, Sara
Landi, Lorenza
Bennati, Chiara
Camerini, Andrea
Toschi, Luca
Putzu, Carlo
Cerea, Giulio
Spitaleri, Gianluca
Cappuzzo, Federico
de Marinis, Filippo
[J]. CLINICAL LUNG CANCER, 2019, 20 (02) : E186 - E194
[7] UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Miura, S.
Maerten, A.
Popat, S.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1405 - S1406
[8] Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
Popat, Sanjay
Hsia, Te-Chun
Hung, Jen-Yu
Jung, Hyun Ae
Shih, Jin-Yuan
Park, Cheol Kyu
Lee, Seung Hyeun
Okamoto, Tatsuro
Ahn, Hee Kyung
Lee, Yong Chul
Sato, Yuki
Lee, Sung Sook
Mascaux, Celine
Daoud, Hasan
Marten, Angela
Miura, Satoru
[J]. ONCOLOGIST, 2022, 27 (04): : 255 - 265
[9] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy
Jinpeng Shi
Hui Yang
Tao Jiang
Xuefei Li
Chao Zhao
Limin Zhang
Sha Zhao
Xiaozhen Liu
Yijun Jia
Yan Wang
Lei Xi
Shijia Zhang
Chunxia Su
Shengxiang Ren
Caicun Zhou
[J]. Chinese Journal of Cancer Research, 2017, 29 (06) : 543 - 552
[10] In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations"
Caliman, Enrico
Petreni, Paolo
Brugia, Marco
Antonuzzo, Lorenzo
Mazzoni, Francesca
[J]. CLINICAL LUNG CANCER, 2020, 21 (05) : E363 - E365

← 1 2 3 4 5 →